The purpose of this registry is to evaluate the outcome of pregnancy in women exposed to VIBATIV at any time during pregnancy. There are no mandated physician visits for the registry.
Study Type
OBSERVATIONAL
Observational
Cumberland Pharmaceuticals Inc.
Nashville, Tennessee, United States
Outcomes of pregnancy in women exposed to VIBATIV at any time during pregnancy
Time frame: Once per trimester, 6-7 months gestation, and within 4 weeks after the estimated due date
Effect of fetal exposure to VIBATIV on pregnancy outcomes
Time frame: Within 4 weeks after the estimated due date and if a live infant birth is reported, at 3, 6, 9, and 12 months of age.
Fetal/neonatal outcomes
Time frame: Within 4 weeks after the estimated due date and if a live infant birth is reported, at 3, 6, 9, and 12 months of age.
Infant development and milestones through 12 months of age
Time frame: Within 4 weeks after the estimated due date and if a live infant birth is reported, at 3, 6, 9, and 12 months of age.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.